Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

[SERRATED COLORECTAL ADENOCARCINOMA].

Nechipay AM, Shishkin KV, Zobnina MV, Cherkasova LM, Krivopuskov VA.

Eksp Klin Gastroenterol. 2016;(3):47-50. Russian.

PMID:
27301141
2.

Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.

Kim SA, Inamura K, Yamauchi M, Nishihara R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald KC, Fuchs CS, Wu K, Chan AT, Zhang X, Ogino S, Qian ZR.

Br J Cancer. 2016 Jan 19;114(2):199-206. doi: 10.1038/bjc.2015.347. Epub 2016 Jan 7.

PMID:
26742007
3.

Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes.

Pérot P, Mullins CS, Naville M, Bressan C, Hühns M, Gock M, Kühn F, Volff JN, Trillet-Lenoir V, Linnebacher M, Mallet F.

Oncotarget. 2015 Nov 24;6(37):40095-111. doi: 10.18632/oncotarget.5539.

4.

The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer.

Chu MM, Liu SS, Tam KF, Ip PP, Cheung AN, Ngan HY.

Int J Gynecol Pathol. 2015 Sep;34(5):403-10. doi: 10.1097/PGP.0000000000000174.

PMID:
26262451
5.

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.

Lenos K, Goos JA, Vuist IM, den Uil SH, Delis-van Diemen PM, Belt EJ, Stockmann HB, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJ, van Vliet SJ.

Oncotarget. 2015 Sep 22;6(28):26278-90. doi: 10.18632/oncotarget.4495.

6.

Preoperative endoscopic tattooing to mark the tumour site does not improve lymph node retrieval in colorectal cancer: a retrospective cohort study.

Feo CV, Portinari M, Zuolo M, Targa S, Matarese VG, Gafà R, Forini E, Lanza G.

J Negat Results Biomed. 2015 May 7;14:9. doi: 10.1186/s12952-015-0027-7.

7.

Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.

Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, Lanza G, Stork-Sloots L, Maru D, Simon I, Capellà G, Salazar R.

Oncologist. 2015 Feb;20(2):127-33. doi: 10.1634/theoncologist.2014-0325. Epub 2015 Jan 5.

8.

Clinical implications of microsatellite instability in T1 colorectal cancer.

Kang J, Lee HW, Kim IK, Kim NK, Sohn SK, Lee KY.

Yonsei Med J. 2015 Jan;56(1):175-81. doi: 10.3349/ymj.2015.56.1.175.

9.

Determinants of recurrence after intended curative resection for colorectal cancer.

Wilhelmsen M, Kring T, Jorgensen LN, Madsen MR, Jess P, Bulut O, Nielsen KT, Andersen CL, Nielsen HJ.

Scand J Gastroenterol. 2014 Dec;49(12):1399-408. doi: 10.3109/00365521.2014.926981. Epub 2014 Nov 5. Review.

PMID:
25370351
10.

KRAS mutation status impacts diagnosis and treatment decision in a patient with two colon tumours: a case report.

Li X, Pezeshkpour G, Phan RT.

J Clin Pathol. 2015 Jan;68(1):83-5. doi: 10.1136/jclinpath-2014-202591. Epub 2014 Oct 13.

PMID:
25313410
11.

Is microsatellite instability really a good prognostic factor of colorectal cancer?

Shin US, Cho SS, Moon SM, Park SH, Jee SH, Jung EJ, Hwang DY.

Ann Coloproctol. 2014 Feb;30(1):28-34. doi: 10.3393/ac.2014.30.1.28. Epub 2014 Feb 28.

12.

Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: predictive role of lymph node metastasis and survival.

Huh JW, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, Lee WY, Chun HK.

J Surg Oncol. 2014 Jun;109(8):848-52. doi: 10.1002/jso.23592. Epub 2014 Mar 13.

PMID:
24623275
13.

Microsatellite instability in the management of stage II colorectal patients.

Strâmbu V, Garofil D, Pop F, Radu P, Brătucu M, Iorga C, Iorga R, Pasnicu C, Ion A, Popa F.

Chirurgia (Bucur). 2013 Nov-Dec;108(6):816-21.

14.

Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis.

Lee H, Flaherty P, Ji HP.

BMC Med Genomics. 2013 Dec 5;6:54. doi: 10.1186/1755-8794-6-54.

15.

The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up.

Powell AG, Ferguson J, Al-Mulla F, Orange C, McMillan DC, Horgan PG, Edwards J, Going JJ.

J Cancer Res Clin Oncol. 2013 Dec;139(12):2013-20. doi: 10.1007/s00432-013-1521-2. Epub 2013 Sep 26.

PMID:
24072233
16.

Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.

Berg M, Guriby M, Nordgård O, Nedrebø BS, Ahlquist TC, Smaaland R, Oltedal S, Søreide JA, Kørner H, Lothe RA, Søreide K.

Mol Med. 2013 Sep 10;19:286-93. doi: 10.2119/molmed.2013.00049.

17.

Lymph node ratio is a stronger prognostic factor than microsatellite instability in colorectal cancer patients: results from a 7 years follow-up study.

Ferri M, Lorenzon L, Onelli MR, La Torre M, Mercantini P, Virgilio E, Balducci G, Ruco L, Ziparo V, Pilozzi E.

Int J Surg. 2013;11(9):1016-21. doi: 10.1016/j.ijsu.2013.05.031. Epub 2013 Jun 6.

18.

Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series.

Merok MA, Ahlquist T, Røyrvik EC, Tufteland KF, Hektoen M, Sjo OH, Mala T, Svindland A, Lothe RA, Nesbakken A.

Ann Oncol. 2013 May;24(5):1274-82. doi: 10.1093/annonc/mds614. Epub 2012 Dec 12.

19.

Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain.

Van Loon K, Venook AP.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1379-86.

PMID:
23138166
20.

Gastrointestinal cancers reactive for the PAb416 antibody against JCV/SV40 T-Ag lack JCV DNA sequences while showing a distinctive pathologic profile.

Chiaravalli AM, Longhi E, Vigetti D, De Stefano FI, Deleonibus S, Capella C, Solcia E, Parravicini C.

J Clin Pathol. 2013 Jan;66(1):44-9. doi: 10.1136/jclinpath-2012-200963. Epub 2012 Sep 25.

PMID:
23012397
Items per page

Supplemental Content

Loading ...
Write to the Help Desk